Form 4 for NPCE NeuroPace Inc
Accepted 2025-02-25 00:00:00 ET · period of report 2024-02-12 · accession 0001415889-25-005576 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-25 | 2024-02-12 | NPCE | Morrell Martha | Chief MEDICAL Off | M - OptEx | $0.03 | +50.0K | 160.3K | +45% | +$1,500 |
| D | 2025-02-25 | 2024-02-12 | NPCE | Morrell Martha | Chief MEDICAL Off | M - OptEx | $0.00 | -50.0K | 140.4K | -26% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-12 | M | A | 50,000 | $0.03 | 160,327 | D | — | — | (F1) Includes 13,847 shares acquired pursuant to the NeuroPace, Inc. 2021 Employee Stock Purchase Plan between April 22, 2021 and June 7, 2024. |
| 2 | Derivative | Stock Option (Rt to Buy) | 2024-02-12 | M | D | 50,000 | $0.00 | 140,449 | D | $0.03 · — to 2030-10-29 | 50,000 Common Stock | (F2) 1/48th of the shares subject to the option vest in equal monthly installments commencing September 19, 2020. If, at the time of the initial public offering, less than 232,371 of the shares subject to this option remain unvested, an amount of shares subject to this option shall vest and become immediately exercisable immediately prior to the offering such that a total of 232,371 shares subject to this option will be vested and immediately exercisable, subject to Dr. Morrells continued service with NeuroPace, Inc. Following such acceleration, the remaining unvested shares subject to this option will continue to vest in equal monthly installments over 48 months. |